// App-Quantinova.ai

: A phase I and randomized phase II study of cabozantinib plus docetaxel and prednisone (C+DP) versus docetaxel and prednisone (DP) alone in metastatic castrate-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Munjid Al Harthy

Principal Investigators

  • Ravi Amrit Madan

  • Fatima Karzai

  • Daniel Peter Petrylak

  • Joseph W. Kim

  • Philip M. Arlen

  • Marc Robert Theoret

  • Jenn Marte

  • Marijo Bilusic

  • Anna Couvillon

  • Guinevere Chun

  • Helen Owens

  • Amy Hankin

  • Lisa M. Cordes

  • William Douglas Figg

  • James L. Gulley

  • William L. Dahut

Medical Centers

  • CCR, NIH, Bethesda, MD

  • National Human Genome Research Institute, National Institutes of Health, Bethesda, MD

  • Yale Cancer Center, New Haven, CT

  • Yale Cancer Center, Yale School of Medicine, New Haven, CT

  • National Cancer Institute, Bethesda, MD

  • National Institute of Health, Bethesda, MD

  • Gastrointestinal Malignancies Section, Center for Cancer Research, National Cancer Institute at the National Institutes of Health, Bethesda, MD

  • National Institute of Health, Bethesda, MD

  • Clinical Pharmacology Program, National Institutes of Health, Bethesda, MD

  • National Human Genome Research Institute, National Institutes of Health, Bethesda, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • Cabozantinib

  • Prednisone

  • Docetaxel

Outcome

  • N/A

Study Design

  • Randomized

  • Fixed Dose

  • Cohort

Phase

  • NA

Study Id's

  • NCT01683994

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved